UBS Global Healthcare Conference
Logotype for Natera Inc

Natera (NTRA) UBS Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Natera Inc

UBS Global Healthcare Conference summary

11 Nov, 2026

Leadership transition

  • Solomon's elevation to CEO follows long involvement in Prospera and Signatera development, clinical strategy, R&D, and commercial rollout.

  • Transition was described as operationally continuous: Solomon already chairs or participates deeply in key decisions, while Steve remains available under a transition agreement.

  • A tenured leadership and sales team, collaborative decision-making, and established commercial processes are expected to preserve execution and customer focus.

Revenue framework and Signatera

  • 2029 framework targets $6B revenue, roughly double the level just above $3B; management characterized it as achievable through multiple volume and ASP paths, without relying on early-detection revenue.

  • Signatera ASP is currently $1,290; management cited ~$1,450 as an achievable 2029 planning level and retained a longer-term goal of $2,000, versus contracted rates in the mid-$3,000s.

  • Reimbursement expansion is a key ASP lever: additional MolDX submissions for tumor types collectively representing up to one-third of volumes, plus progress in biomarker states and Medicare Advantage compliance.

  • MRD remains early, with estimated single-digit penetration of a $15B-$30B annual revenue market; Signatera is expected to exceed $1B revenue this year.

Volume growth and investment

  • The latest quarter recorded 318,000 units and 33,000 sequential growth; year-on-year volume growth was 113,000 units, a record by more than 10,000.

  • Management said year-on-year volume growth is now more useful than sequential changes for assessing acceleration; trailing four-quarter averages also remain relevant.

  • Signatera commercial staffing aspiration is 300-400 people, with continued iteration and growth expected; incremental investment emphasis remains on R&D, especially clinical trials.

  • Most OpEx growth this year and next is directed to R&D; ~$100M of this year's $900M-$950M-plus R&D budget is for colorectal cancer and early detection, with no current top-line contribution.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Natera